Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Eugen FeistSaeed FatenejadSergey GrishinElena KornevaMichael E LuggenEvgeniy NasonovMikhail SamsonovJosef S SmolenRoy M FleischmannPublished in: Annals of the rheumatic diseases (2022)
NCT02760433.